MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 130 filers reported holding MERSANA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $163,915 | -66.4% | 129,067 | -13.1% | 0.00% | – |
Q2 2023 | $488,443 | +14.4% | 148,463 | +42.9% | 0.00% | – |
Q1 2023 | $426,943 | -25.3% | 103,879 | +6.6% | 0.00% | -100.0% |
Q4 2022 | $571,197 | -17.6% | 97,474 | -5.1% | 0.00% | 0.0% |
Q3 2022 | $693,000 | +85.8% | 102,667 | +27.5% | 0.00% | – |
Q2 2022 | $373,000 | +22.7% | 80,542 | +6.0% | 0.00% | – |
Q1 2022 | $304,000 | -26.7% | 75,957 | +13.8% | 0.00% | – |
Q4 2021 | $415,000 | -15.7% | 66,721 | +28.1% | 0.00% | – |
Q3 2021 | $492,000 | -33.2% | 52,096 | -3.8% | 0.00% | – |
Q2 2021 | $736,000 | -14.7% | 54,157 | +1.3% | 0.00% | – |
Q1 2021 | $863,000 | -71.4% | 53,442 | -52.8% | 0.00% | -100.0% |
Q4 2020 | $3,013,000 | +43.5% | 113,240 | +0.4% | 0.00% | 0.0% |
Q3 2020 | $2,100,000 | +55.3% | 112,743 | +95.2% | 0.00% | 0.0% |
Q2 2020 | $1,352,000 | +7852.9% | 57,772 | +431.6% | 0.00% | – |
Q3 2019 | $17,000 | – | 10,868 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |